Last updated on February 2018

Safety and Biological Activity of Vesatolimod in HIV-1 Infected Virologically Suppressed Adults

Brief description of study

The primary objectives of this study are to evaluate the safety and tolerability of a 6-dose regimen of vesatolimod (formerly GS-9620) (at 1 mg, 2 mg, and 4 mg dose levels) in HIV-1 infected virologically suppressed adults on antiretroviral therapy (ART) and to evaluate the virologic effect of vesatolimod as measured by changes in plasma HIV-1 RNA.

Clinical Study Identifier: NCT02858401

Contact Investigators or Research Sites near you

Start Over

Anthony Mills, MD

Mills Clinical Research
Los Angeles, CA United States
  Connect »

Constance A Benson, MD

UCSD Antiviral Research Center (AVRC)
San Diego, CA United States
  Connect »

Michael F. Para, MD

Ohio State University Infectious Diseases Research
Columbus, OH United States
  Connect »

Sharon Anne Riddler, MD

University of Pittsburgh
Pittsburgh, PA United States
  Connect »